FrancophonIA/ELRC3.0 huggingface dataset:
English: Empagliflozin and linagliptin as single agents showed an incidence of hypoglycaemia comparable to placebo when used alone or in combination with other antidiabetics not known to cause hypoglycaemia (e.g. metformin, thiazolidinediones).
Danish: Empagliflozin og linagliptin som enkeltstoffer viste en hyppighed af hypoglykæmi, som er sammenlignelig med placebo, når de blev anvendt alene eller i kombination med antidiabetika, der ikke er kendt for at forårsage hypoglykæmi (f.eks. metformin, glitazoner).
English: - The active substances are empagliflozin and linagliptin.
Danish: - Aktive stoffer: empagliflozin og linagliptin.
English: Co-administration of rifampicin decreased linagliptin exposure by 40 %, suggesting that the efficacy of linagliptin may be reduced when administered in combination with a strong P-glycoprotein (P-gp) or cytochrome P450 (CYP) isozyme CYP3A4 inducer, particularly if these are administed long-term (see section 5.2).
Danish: Samtidig administration af rifampicin nedsatte linagliptin-eksponeringen med 40 %, hvilket tyder på, at linagliptins virkning kan reduceres, når det indgives i kombination med en potent induktor af P-glykoprotein (P-gp) eller CYP3A4, specielt hvis disse indgives langvarigt (se pkt.
English: The mean age was 63 years, the mean HbA1c was 8.1 %, and 71.5 % were male.
Danish: Gennemsnitsalderen var 63 år, gennemsnitlig HbA1c var 8,1 %, og 71,5 % var mænd.
English: The mean age was 64 years, the mean HbA1c was 7.15 %, and 60 % were male.
Danish: Gennemsnitsalderen var 64 år, gennemsnitlig HbA1c var 7,15 % og 60 % var mænd.
English: General toxicity studies in rats up to 13 weeks were performed with the combination of empagliflozin and linagliptin.
Danish: Der blev udført generelle toksicitetsstudier med kombinationen af empagliflozin og linagliptin hos rotter i op til 13 uger.
English: Only at maternally toxic doses, linagliptin caused a slight retardation of skeletal ossification in the rat and increased embryofoetal loss in the rabbit.
Danish: Kun ved maternelt toksiske doser forårsagede linagliptin en lille forsinkelse af skeletknogledannelsen hos rotter og øget embryoføtalt tab hos kaniner.
English: With once daily dosing, steady state plasma concentrations of empagliflozin were reached by the fifth dose.
Danish: Ved dosering af empagliflozin en gang dagligt blev steady state plasmakoncentrationen nået efter den femte dosis.
English: Your doctor may ask you to take a different medicine.
Danish: Din læge kan beslutte, at du skal have et andet lægemiddel.
English: A total of 6979 patients were treated (linagliptin 5 mg: 3494, placebo: 3485) and followed for a median of 2.2 years.
Danish: I alt 6979 patients blev behandlet (linagliptin 5 mg: 3494, placebo: 3485) og fulgt i en mediantid på 2,2 år.
English: C] linagliptin dose to healthy subjects, approximately 85 % of the administered radioactivity was eliminated in faeces (80 %) or urine (5 %) within 4 days of dosing.
Danish: C]-linagliptin til raske frivillige blev ca. 85 % af den indgivne radioaktivitet udskilt i fæces (80 %) eller urin (5 %) inden for 4 dage efter doseringen.
English: Glyxambi, fixed dose combination of empagliflozin and linagliptin, is indicated in adults aged 18 years and older with type 2 diabetes mellitus:
Danish: Glyxambi, fastdosis-kombination af empagliflozin og linagliptin, er indiceret til voksne med type 2diabetes mellitus i alderen 18 år og derover:
English: No increased risk of CV death or all-cause mortality was observed.
Danish: Der blev ikke observeret nogen øget risiko for kardiovaskulær mortalitet eller mortalitet uanset årsag.
English: Microscopic evidence of the effects of exaggerated pharmacology on the kidney observed in some species included tubular dilatation, and tubular and pelvic mineralisation at approximately 4-times the clinical AUC exposure of empagliflozin associated with the 25 mg dose.
Danish: Den mikroskopiske evidens for virkningerne af overdreven farmakologisk effekt på nyrerne, der blev observeret hos visse arter, inkluderede tubulær dilatation og mineralisering i tubuli og pelvis ved ca. 4 gange den kliniske AUC-eksponering for empagliflozin ved en dosis på 25 mg.
English: Based on the mode of action of SGLT2 inhibitors, osmotic diuresis accompanying therapeutic glucosuria may lead to a modest decrease in blood pressure (see section 5.1).
Danish: På baggrund af SGLT2-hæmmeres virkningsmekanisme kan den osmotiske diurese, som ledsager terapeutisk glukosuri, medføre et beskedent blodtryksfald (se pkt.
English: In patients with mild, moderate or severe renal impairment (eGFR <30 to <90 mL/min/1.73 m2) and patients with kidney failure or end stage renal disease (ESRD), AUC of empagliflozin increased by approximately 18 %, 20 %, 66 %, and 48 %, respectively compared to subjects with normal renal function.
Danish: Hos patienter med let, moderat eller svært nedsat nyrefunktion (eGFR < 30 til < 90 ml/min/1,73 m og patienter med nyresvigt/terminal nyreinsufficiens steg empagliflozins AUC med henholdsvis ca. 18 %, 20 %, 66 % og 48 %, sammenlignet med patienter med normal nyrefunktion.
English: A higher risk of volume depletion adverse reactions were reported in patients aged 75 years and older, treated with empagliflozin, especially at 25 mg/day (see section 4.8).
Danish: Der blev rapporteret en højere risiko for volumendepletering hos patienter på 75 år og derover, som blev behandlet med empagliflozin, specielt ved 25 mg/dag (se pkt.
English: Do not use this medicine if you are breast-feeding.
Danish: Lad være med at tage dette lægemiddel, hvis du ammer.
English: The information about adverse reactions not reported in Glyxambi clinical trials is based on the experience from empagliflozin and linagliptin.
Danish: Oplysningerne om bivirkninger, der ikke er rapporteret fra kliniske studier med Glyxambi, er baseret på erfaringer med empagliflozin og linagliptin.
English: Furthermore GLP-1 also reduces glucagon secretion from pancreatic alpha cells, resulting in a reduction in hepatic glucose output.
Danish: Desuden nedsætter GLP-1 glucagonsekretionen fra bugspytkirtlens alfaceller, hvilket medfører en nedsat glucoseproduktion i leveren.
English: Empagliflozin improves both fasting and post prandial plasma glucose levels.
Danish: Empagliflozin forbedrer både faste-plasmaglucose og postprandial plasmaglucose.
English: A total of 6033 patients were treated (linagliptin 5 mg: 3023, glimepiride 1 mg to 4 mg: 3010) and followed for a median of 6.25 years.
Danish: I alt 6033 patienter blev behandlet (linagliptin 5 mg: 3023, glimepirid 1 mg til 4 mg: 3010) og fulgt i en mediantid på 6,25 år.
English: Empagliflozin exposure is increased in patients with severe hepatic impairment and therapeutic experience in such patients is limited (see section 5.2).
Danish: Hos patienter med svært nedsat leverfunktion er eksponeringen for empagliflozin øget, men den kliniske erfaring hos sådanne patienter er begrænset (se pkt.
English: When used in combination with antidiabetics known to cause hypoglycaemia (e.g. sulphonylureas and/or insulin), the incidence of hypoglycaemia of both agents was increased (see section 4.8).
Danish: Ved anvendelse i kombination med antidiabetika, der er kendt for at forårsage hypoglykæmi (f.eks. sulfonylurinstoffer og/eller insulin), øgedes hyppigheden af hypoglykæmi for begge præparater (se pkt.
English: In patients with end-stage renal disease or in patients on dialysis, Glyxambi should not be used, as empagliflozin is not expected to be effective in these patients (see section 5.2).
Danish: Patienter med terminal nyresygdom og patienter i dialyse bør ikke tage Glyxambi, da empagliflozin ikke forventes at virke hos disse patienter (se pkt.
English: Animal studies show that empagliflozin and linagliptin cross the placenta during late gestation, but do not indicate direct or indirect harmful effects with respect to early embryonic development with either empagliflozin or linagliptin (see section 5.3).
Danish: Dyrestudier viser, at empagliflozin og linagliptin passerer placenta sent i graviditeten, men indikerer hverken direkte eller indirekte skadelige virkninger, hvad angår den tidlige fosterudvikling (se pkt.
English: An interaction study with gemfibrozil, an in vitro inhibitor of OAT3 and OATP1B1/1B3 transporters, showed that empagliflozin Cmax increased by 15 % and AUC increased by 59 % following coadministration.
Danish: Et interaktionsstudie med gemfibrozil, en in vitro-hæmmer af transportproteinerne OAT3 og OATP1B1/1B3, viste, at empagliflozin-Cmax steg med 15 % og -AUC med 59 % efter samtidig indgivelse.
English: • if you are 75 years old or older as starting this medicine above 75 years is not recommended .
Danish: • du bør ikke påbegynde behandling med dette lægemiddel, hvis du er 75 år eller derover.
English: Table 2 Efficacy parameters in clinical study comparing Glyxambi to individual active substances as add-on therapy in patients inadequately controlled on metformin
Danish: Effektparametre i et klinisk studie, der sammenligner Glyxambi med de enkelte aktive stoffer som tillægsterapi hos patienter, der er utilstrækkeligt kontrolleret på metformin
English: Tablet core: mannitol (E421), pre-gelatinised starch (maize), maize starch, copovidone, crospovidone, talc and magnesium stearate.
Danish: Tabletkerne: mannitol (E421), prægelatineret majsstivelse, majsstivelse, copovidon, crospovidon, talcum og magnesiumstearat.
English: Linagliptin did not increase the risk of the combined endpoint of CV death, non-fatal myocardial infarction or non-fatal stroke (MACE-3) [Hazard Ratio (HR)=0.98; (95 % CI 0.84, 1.14); p<0.0001 for non-inferiority], when added to standard of care in adult patients with type 2 diabetes with increased CV risk compared to glimepiride (see Table 6).
Danish: Linagliptin øgede ikke risikoen for det kombinerede endepunkt kardiovaskulær mortalitet, ikke-dødeligt myokardieinfarkt eller ikkedødelig apopleksi (MACE-3) [Hazard Ratio (HR)=0,98; (95 % CI 0,84; 1,14); p<0,0001 for noninferioritet], når det blev tilføjet til standardbehandling hos voksne patienter med type 2-diabetes med en forhøjet kardiovaskulær risiko, sammenlignet med glimepirid (se tabel 6).
English: Your doctor may ask you to stop taking Glyxambi until you recover, to prevent loss of too much body fluid.
Danish: Lægen kan beslutte, at du skal holde pause med at tage Glyxambi, indtil du er rask, for at forhindre, at du mister for meget kropsvæske.
English: In moderate renal impairment, a moderate increase in exposure of about 1.7-fold was observed compared with control.
Danish: Hos patienter med moderat nedsat nyrefunktion sås en moderat øget eksponering på ca. 1,7 gange sammenlignet med kontrolgruppen.
English: In addition patients with T2DM and severe renal impairment (<30 mL/min) were compared to T2DM patients with normal renal function.
Danish: Desuden blev patienter med type 2-diabetes og svært nedsat nyrefunktion (< 30 ml/min) sammenlignet med patienter med type 2-diabetes og normal nyrefunktion.
English: After 24 weeks, rescue therapy was used in 4 (3.6 %) patients treated with empagliflozin 25 mg and in 2 (1.8 %) patients treated with empagliflozin 10 mg, compared to 13 (12.0 %) patients treated with placebo (all patients on background metformin + linagliptin 5 mg).
Danish: Efter 24 uger blev nødbehandling anvendt hos 4 (3,6 %) patienter, der fik empagliflozin 25 mg, og hos 2 (1,8 %) patienter, der fik empagliflozin 10 mg, sammenlignet med 13 (12,0 %) patienter, der fik placebo (alle patienter på baggrunds-metformin + linagliptin 5 mg).
English: In Glyxambi clinical trials, the incidence of urinary tract infections was overall similar between the patients treated with Glyxambi and the patients treated with empagliflozin or linagliptin.
Danish: I kliniske studier med Glyxambi var forekomsten af urinvejsinfektioner stort set ens hos patienter, der fik Glyxambi, og patienter, der fik empagliflozin eller linagliptin.
English: An urge to pass urine or more frequent urination may be due to the way this medicine works, but as they can also be signs of urinary tract infection, if you note an increase in such symptoms, you should also contact your doctor.
Danish: En stærk vandladningstrang eller hyppigere vandladning kan skyldes den måde, dette lægemiddel virker på, men kan også være et tegn på en urinvejsinfektion.
English: Vaginal moniliasis, vulvovaginitis, balanitis and other genital infections Nasopharyngitis
Danish: Vaginal moniliasis, vulvovaginitis, balanitis og andre genitale infektioner Nasofaryngitis
English: Approximately 19 % of the population had an eGFR of 45-60 mL/min/1.73 m2, 28 % of 30-45 mL/min/1.73 m2 and 15 % of <30 mL/min/1.73 m².
Danish: Ca. 19 % af populationen havde en eGFR på 45-60 ml/min/1,73 m2, 28 % på 30-45 ml/min/1,73 m2 og 15 % på < 30 ml/min/1,73 m².
English: • laboratory blood tests may show changes in blood fat levels, an increase in the amount of red blood cells (increase in haematocrit), and changes related to kidney function (decrease in filtration rate and increase in blood creatinine)
Danish: • blodprøver kan vise ændringer i blodets indhold af fedt, et højere antal røde blodlegemer
English: Interaction studies conducted in healthy volunteers suggest that the pharmacokinetics of linagliptin were not influenced by co-administration with metformin and glibenclamide.
Danish: Interaktionsstudier med raske frivillige forsøgspersoner tyder på, at der ikke sker nogen påvirkning af linagliptins farmakokinetik ved administration sammen med metformin og glibenclamid.
English: Mean percent increases from baseline for Glyxambi 10 mg/5 mg and 25 mg/5 mg versus placebo, respectively, were total cholesterol 3.2% and 4.6% versus 0.5%; HDL-cholesterol 8.5% and 6.2% versus 0.4%; LDL-cholesterol 5.8% and 11.0% versus 3.3%; triglycerides -0.5% and 3.3% versus 6.4 %.
Danish: De gennemsnitlige procentvise stigninger fra baseline for Glyxambi henholdsvis 10 mg/5 mg og 25 mg/5 mg versus placebo var for total-kolesterol 3,2 % og 4,6 % versus 0,5 %; HDL-kolesterol 8,5 % og 6,2 % versus 0,4 %; LDL-kolesterol 5,8 % og 11,0 % versus 3,3 %; triglycerider -0,5 % og 3,3 % versus 6,4 %.
English: A total of 2,173 patients with type 2 diabetes mellitus and inadequate glycaemic control were treated in clinical studies to evaluate the safety and efficacy of Glyxambi; 1,005 patients were treated with Glyxambi 10 mg empagliflozin/5 mg linagliptin or 25 mg empagliflozin/5 mg linagliptin.
Danish: I alt 2.173 patienter med type 2-diabetes og utilstrækkelig glykæmisk kontrol blev behandlet i kliniske studier for at vurdere Glyxambis sikkerhed og effekt; 1.005 patienter blev behandlet med Glyxambi 10 mg empagliflozin/5 mg linagliptin eller 25 mg empagliflozin/5 mg linagliptin.
English: Co-administration of empagliflozin with probenecid, an inhibitor of UGT enzymes and OAT3, resulted in a 26 % increase in peak empagliflozin plasma concentrations (Cmax) and a 53 % increase in area under the concentration-time curve (AUC).
Danish: Samtidig administration af empagliflozin og probenecid, en hæmmer af UGT-enzymer og OAT3, medførte en stigning på 26 % i peak-plasmakoncentrationen af empagliflozin (Cmax) og en stigning på 53 % i arealet under koncentration/tid-kurven (AUC).
English: Inhibition of SGLT2 in patients with type 2 diabetes mellitus and hyperglycaemia leads to excess glucose excretion in the urine.
Danish: Hæmning af SGLT2 hos patienter med type 2-diabetes og hyperglykæmi medfører øget udskillelse af glucose i urinen.
English: Glyxambi combines two antihyperglycaemic medicinal products with complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: empagliflozin, a sodium-glucose co-transporter (SGLT2) inhibitor, and linagliptin, DPP-4 inhibitor.
Danish: Glyxambi kombinerer to antihyperglykæmiske lægemidler med komplementære virkningsmekanismer for at forbedre den glykæmiske kontrol hos patienter med type 2-diabetes: empagliflozin, en natriumglucose-co-transportprotein (SGLT2)-hæmmer, og linagliptin, en DPP-4-hæmmer.
English: The treatment with Glyxambi resulted in statistically significant improvements in HbA1c and fasting plasma glucose (FPG) compared to linagliptin 5 mg and also compared to empagliflozin 10 mg or 25 mg. Glyxambi also provided statistically significant improvements in body weight compared to linagliptin 5 mg.
Danish: Behandlingen med Glyxambi resulterede i statistisk signifikante forbedringer i HbA1c og faste-plasmaglucose (FPG) sammenlignet med linagliptin 5 mg og med empagliflozin 10 mg eller 25 mg. Glyxambi gav også statistisk signifikante forbedringer i kropsvægt sammenlignet med linagliptin 5 mg.
English: Table 1 Adverse reactions System organ class
Danish: Bivirkninger Systemorganklasse
English: What Glyxambi contains - The active substances are empagliflozin and linagliptin.
Danish: Glyxambi indeholder - Aktive stoffer: empagliflozin og linagliptin.
English: After once daily dosing of 5 mg linagliptin, steady-state plasma concentrations are reached by the third dose.
Danish: Efter administration af 5 mg linagliptin én gang dagligt opnåedes steady state plasmakoncentrationer efter tredje dosis.
English: In patients with mild, moderate and severe hepatic insufficiency (Child-Pugh classification), mean AUC and Cmax of empagliflozin increased (AUC by 23 %, 47 %, 75 % and Cmax by 4 %, 23 %,48 %) compared to subjects with normal hepatic function (see section 4.2).
Danish: Hos patienter med let, moderat og svært nedsat leverfunktion (Child-Pugh-klassifikation) steg empagliflozins gennemsnitlige AUC og Cmax (AUC med henholdsvis 23 %, 47 % og 75 % og Cmax med 4 %, 23 % og 48 %) sammenlignet med patienter med normal leverfunktion (se pkt.
English: Pharmacokinetics were generally similar in healthy subjects and in patients with type 2 diabetes.
Danish: Farmakokinetikken hos raske forsøgspersoner og hos patienter med type 2-diabetes var generelt ens.
English: Glyxambi is available in PVC/PVDC/aluminium perforated unit dose blisters.
Danish: Glyxambi fås i perforerede enkeltdosisblistere af PVC/PVDC/aluminium.
English: The single dose and steady state pharmacokinetic parameters of empagliflozin were similar suggesting linear pharmacokinetics with respect to time.
Danish: De farmakokinetiske parametre for empagliflozin efter en enkeltdosis og ved steady state var de samme, hvilket tyder på en lineær farmakokinetik for så vidt angår tid.
English: Urinary tract infection was reported more frequently in female patients treated with empagliflozin compared to placebo, but not in male patients.
Danish: Urinvejsinfektion blev rapporteret hyppigere hos kvinder, der blev behandlet med empagliflozin, sammenlignet med placebo, mens der ingen forskel var hos mænd.
English: Based on the experience with empagliflozin and linagliptin, an increase of the risk of hypoglycaemia is expected with the concomitant treatment of insulin and /or sulphonylurea (see section 4.4 and information below)
Danish: Baseret på erfaringen med empagliflozin og linagliptin forventes en øget risiko for hypoglykæmi ved samtidig behandling med insulin og/eller sulfonylurinstof (se pkt.
English: The steady state mean plasma area under the concentration-time curve (AUC) and Cmax were 1,870 nmol.h and 259 nmol/L with empagliflozin 10 mg and 4,740 nmol.h and 687 nmol/L with empagliflozin 25 mg once daily.
Danish: Ved steady state var middelarealet under plasmakoncentration/tid-kurven (AUC) og Cmax 1.870 nmol x time og 259 nmol/l for empagliflozin 10 mg én gang dagligt og 4.740 nmol x time og 687 nmol/l for empagliflozin 25 mg én gang dagligt.
English: • shaking, sweating, feeling very anxious or confused, fast heart beat
Danish: • rysteture, svedtendens, ængstelse eller forvirring, hurtig hjerterytme (puls)
English: Baseline (mean) Change from baseline (adjusted mean) Comparison vs. placebo (adjusted mean) (95 % CI)
Danish: Baseline (middelværdi) Ændring fra baseline (justeret middelværdi) Sammenligning med placebo (justeret middelværdi) (95 % CI)
English: Safety and efficacy of Glyxambi in paediatric patients below 18 years of age have not been established.
Danish: Glyxambis sikkerhed og virkning hos børn og unge under 18 år er ikke klarlagt.
English: In empagliflozin trials, vaginal moniliasis, vulvovaginitis, balanitis and other genital infections were reported more frequently for empagliflozin 10 mg (4.0 %) and empagliflozin 25 mg (3.9 %) compared to placebo (1.0 %).
Danish: I studier med empagliflozin blev vaginal moniliasis, vulvovaginitis, balanitis og andre genitale infektioner rapporteret hyppigere for empagliflozin 10 mg (4,0 %) og empagliflozin 25 mg (3,9 %) end for placebo (1,0 %).
English: Linagliptin is not expected to be eliminated to a therapeutically significant degree by haemodialysis or peritoneal dialysis.
Danish: Linagliptin forventes ikke at blive fjernet i klinisk signifikant grad ved hæmodialyse eller peritonealdialyse.
English: Hypoglycaemia with empagliflozin
Danish: Hypoglykæmi ved empagliflozin
English: Based on very limited experience in patients 75 years and older, initiation of Glyxambi therapy is not recommended in this population (see sections 4.4 and 5.2).
Danish: Den kliniske erfaring er meget begrænset hos patienter på 75 år og derover, og påbegyndelse af Glyxambi-behandling kan ikke anbefales hos denne population (se pkt.
English: Effects of empagliflozin on other medicinal products
Danish: Empagliflozins indvirkning på andre lægemidler
English: In addition, urinary glucose excretion triggers calorie loss, associated with body fat loss and body weight reduction.
Danish: Udskillelse af glucose i urinen udløser desuden kalorietab og herunder tab af kropsfedt og vægtreduktion.
English: • medicines that might have an effect on the break down of empagliflozin or linagliptin in your body such as rifampicin (an antibiotic used to treat tuberculosis) or certain medicines used to treat seizures (such as carbamazepine, phenobarbital or phenytoin).
Danish: • Rifampicin (et antibiotikum, der bruges til behandling af tuberkulose) og visse lægemidler, der bruges til behandling af krampeanfald (f.eks. carbamazepin, phenobarbital eller phenytoin).
English: Driving and using machines Glyxambi has minor influence on the ability to drive and use machines.
Danish: Trafik- og arbejdssikkerhed Glyxambi påvirker i mindre grad evnen til at føre motorkøretøj og betjene maskiner.
English: Linagliptin 5 mg in patients inadequately controlled on metformin and empagliflozin 10 mg or empagliflozin 25 mg
Danish: Linagliptin 5 mg hos patienter, der er utilstrækkeligt kontrolleret på metformin og empagliflozin 10 mg eller 25 mg
English: Empagliflozin is mainly excreted unchanged.
Danish: Empagliflozin udskilles i det væsentlige uomdannet.
English: Glyxambi is added to metformin and/or sulphonylurea (SU) to treat type 2 diabetes in adult patients whose diabetes cannot be controlled when treated with metformin and/or sulphonylurea in combination with empagliflozin, or when treated with metformin and/or sulphonylurea in combination with linagliptin.
Danish: Glyxambi bruges som tillæg til metformin og/eller sulfonylurinstof (SU) til at behandle type 2-diabetes hos voksne patienter, når metformin og/eller sulfonylurinstof i kombination med empagliflozin eller linagliptin, ikke er tilstrækkeligt til at kontrollere diabetes.
English: In addition, linagliptin is not expected to be eliminated to a therapeutically significant degree by haemodialysis or peritoneal dialysis (see section 4.2).
Danish: Linagliptin forventes derudover ikke at blive elimineret i en terapeutisk signifikant grad ved hæmodialyse eller peritonealdialyse (se pkt.
English: The usual starting dose is 10 mg empagliflozin plus 5 mg linagliptin once a day.
Danish: Den sædvanlige startdosis er 10 mg empagliflozin plus 5 mg linagliptin én gang dagligt.
English: By blocking this protein, the medicine causes glucose (blood sugar), sodium (salt) and water to be removed via the urine.
Danish: Når Glyxambi blokerer SGLT2-proteinet, bliver glukose (sukker), natrium (salt) og vand fjernet via urinen.
English: • if you develop symptoms of acute pancreatitis, like persistent, severe abdominal pain.
Danish: • hvis du får symptomer på akut betændelse i bugspytkirtlen (pankreatitis) fx vedvarende, svære mavesmerter.